On June 17, Shougang LanzaTech fell 5.19% in regular trading, trading at 41.16 HKD/share, with turnover of approximately 13.35 million HKD. The decline reflects continued profit-taking pressure following a cumulative gain exceeding 180% since the company's IPO on June 3 at an issue price of 14.6 HKD/share.
The stock had previously surged on multiple catalysts, including the successful commencement of trial production at the world's first CO-based bioethanol synthesis project and the rapid expansion of the global sustainable aviation fuel (SAF) market. Shares touched a high of 44.58 HKD before retreating. The company plans to construct an SAF facility in Baotou, Inner Mongolia, with production targeted for next year.
On the fundamental side, Shougang LanzaTech has explicitly stated it cannot achieve net profit breakeven in the near term. Its IPO international placement was only 0.95x subscribed, reflecting cautious institutional sentiment. As the world's largest CCUS enterprise utilizing synthetic biology technology — commanding a 58.4% global market share by revenue — valuation digestion pressure remains elevated following the rapid post-listing rally.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments